These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
140 related articles for article (PubMed ID: 1384919)
1. A 12-week placebo-controlled double-blind study of prazosin in the treatment of prostatic obstruction due to benign prostatic hyperplasia. Chapple CR; Stott M; Abrams PH; Christmas TJ; Milroy EJ Br J Urol; 1992 Sep; 70(3):285-94. PubMed ID: 1384919 [TBL] [Abstract][Full Text] [Related]
2. A twelve-week placebo-controlled study of prazosin in the treatment of prostatic obstruction. Chapple CR; Christmas TJ; Milroy EJ Urol Int; 1990; 45 Suppl 1():47-55. PubMed ID: 1690482 [TBL] [Abstract][Full Text] [Related]
3. A multicenter, double-blind, placebo-controlled trial of the efficacy of prazosin in the treatment of dysuria associated with benign prostatic hypertrophy. Le Duc A; Cariou G; Baron C; Cukier J; Quentel P; Faure G; Rambeaud JJ; Navratil H; Costa P; Richaud JJ Urol Int; 1990; 45 Suppl 1():56-62. PubMed ID: 1690483 [TBL] [Abstract][Full Text] [Related]
4. Prazosin in the treatment of prostatic obstruction. A placebo-controlled study. Kirby RS; Coppinger SW; Corcoran MO; Chapple CR; Flannigan M; Milroy EJ Br J Urol; 1987 Aug; 60(2):136-42. PubMed ID: 2444306 [TBL] [Abstract][Full Text] [Related]
5. Alpha-blocking treatment with alfuzosin in symptomatic benign prostatic hyperplasia: comparative study with prazosin. The PRAZALF Group. Buzelin JM; Hebert M; Blondin P Br J Urol; 1993 Dec; 72(6):922-7. PubMed ID: 7508331 [TBL] [Abstract][Full Text] [Related]
6. Effects of an alpha 1-adrenergic blocker (prazosin HCl) on micturition disturbances associated with benign prostatic hypertrophy. Shimizu K; Nakai K; Imai K; Yamanaka H Urol Int; 1990; 45 Suppl 1():36-9. PubMed ID: 1690479 [TBL] [Abstract][Full Text] [Related]
7. [A double-blind trial on the effect of bunazosin hydrochloride for the symptoms of benign prostatic hypertrophy]. Kumamoto Y; Tsukamoto T; Yachiku S; Kaneko S; Koyanagi T; Togashi M; Maru A; Tsuchida S; Nishizawa O; Orikasa S Hinyokika Kiyo; 1990 Oct; 36(10):1213-32. PubMed ID: 1702262 [TBL] [Abstract][Full Text] [Related]
8. Silodosin therapy for lower urinary tract symptoms in men with suspected benign prostatic hyperplasia: results of an international, randomized, double-blind, placebo- and active-controlled clinical trial performed in Europe. Chapple CR; Montorsi F; Tammela TL; Wirth M; Koldewijn E; Fernández Fernández E; Eur Urol; 2011 Mar; 59(3):342-52. PubMed ID: 21109344 [TBL] [Abstract][Full Text] [Related]
9. Effects of prazosin HCl on micturition disturbance associated with benign prostatic hypertrophy and bladder neck contracture. Kohama Y; Watanabe H; Sen Y; Yamamoto Y; Morioka M; Fujita Y Urol Int; 1990; 45 Suppl 1():26-9. PubMed ID: 1690477 [TBL] [Abstract][Full Text] [Related]
10. Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study. Roehrborn CG; McVary KT; Elion-Mboussa A; Viktrup L J Urol; 2008 Oct; 180(4):1228-34. PubMed ID: 18722631 [TBL] [Abstract][Full Text] [Related]
11. Clinical studies on the effectiveness of prazosin HCl (Minipress tablets) in the treatment of dysuria accompanying benign prostatic hyperplasia. Aoki H; Ohninata M; Tsuzuki T; Ohhori M; Shiraiwa Y; Yamaguchi O; Kobayashi M; Yokota T; Numazato S; Sakuma S Urol Int; 1990; 45 Suppl 1():18-25. PubMed ID: 1690476 [TBL] [Abstract][Full Text] [Related]
12. Effects of prazosin and carbachol in patients with benign prostatic obstruction. Hedlund H; Andersson KE Scand J Urol Nephrol; 1988; 22(1):19-22. PubMed ID: 2455331 [TBL] [Abstract][Full Text] [Related]
13. Urodynamic effects of once daily tadalafil in men with lower urinary tract symptoms secondary to clinical benign prostatic hyperplasia: a randomized, placebo controlled 12-week clinical trial. Dmochowski R; Roehrborn C; Klise S; Xu L; Kaminetsky J; Kraus S J Urol; 2010 Mar; 183(3):1092-7. PubMed ID: 20092847 [TBL] [Abstract][Full Text] [Related]
14. Efficacy and side-effects of prazosin as a symptomatic treatment of benign prostatic obstruction. Ruutu ML; Hansson E; Juusela HE; Permi JE; Rusk JI; Sotarauta MT; Talja MT; Wuokko EJ; Mattila MJ Scand J Urol Nephrol; 1991; 25(1):15-9. PubMed ID: 1710823 [TBL] [Abstract][Full Text] [Related]
15. Clinical evaluation of effects of prazosin in patients with benign prostatic obstruction. A double-blind, multi-institutional, Paraprost-controlled study. Yamaguchi O; Shiraiwa Y; Kobayashi M; Yokota T; Ohinata M; Aoki H; Tsuzuki T; Ohori M Urol Int; 1990; 45 Suppl 1():40-6. PubMed ID: 1690481 [TBL] [Abstract][Full Text] [Related]
16. Urodynamic effects of terazosin treatment for Japanese patients with symptomatic benign prostatic hyperplasia. Tanaka Y; Masumori N; Itoh N; Sato Y; Takahashi A; Ogura H; Furuya S; Tsukamoto T J Urol; 2002 Jun; 167(6):2492-5. PubMed ID: 11992065 [TBL] [Abstract][Full Text] [Related]
17. Effects of prazosin in patients with benign prostatic obstruction. Hedlund H; Andersson KE; Ek A J Urol; 1983 Aug; 130(2):275-8. PubMed ID: 6192252 [TBL] [Abstract][Full Text] [Related]
18. Long-term treatment of benign prostatic hyperplasia with alfuzosin: a 12-18 month assessment. BPHALF Group. Jardin A; Bensadoun H; Delauche-Cavallier MC; Attali P Br J Urol; 1993 Nov; 72(5 Pt 1):615-20. PubMed ID: 10071548 [TBL] [Abstract][Full Text] [Related]
19. Assessment of the antihypercholesterolemic drug, Probucol, in benign prostatic hyperplasia. Resnick MI; Jackson JE; Watts LE; Boyce WH J Urol; 1983 Jan; 129(1):206-9. PubMed ID: 6186824 [TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of once-daily alfuzosin in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a randomized, placebo-controlled trial. Roehrborn CG Urology; 2001 Dec; 58(6):953-9. PubMed ID: 11744466 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]